HighTide Therapeutics rides NASH R&D wave with a $107M raise
HighTide Therapeutics has raised a $107 million Series C round to fund mid-stage studies in metabolic and digestive diseases, with the goal of filing for approval in China within two to three years.
HighTide, which has roots in Shenzhen, China, and Maryland, disclosed the round Thursday morning in advance of the JPMorgan healthcare meeting. CEO and founder Liping Liu told Endpoints News the financing would likely bankroll the company into the 2024 to 2025 timeframe.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.